Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
Status:
RECRUITING
Trial end date:
2025-03-05
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischemic heart failure.